Cargando…
Safety of anti-CGRP monoclonal antibodies in patients with migraine during the COVID-19 pandemic: Present and future implications
BACKGROUND AND OBJECTIVE: CGRP, a neuropeptide involved in migraine pathophysiology, is also known to play a role in the respiratory system and in immunological conditions such as sepsis. We analyzed the impact of the use of CGRP antagonists in patients with migraine during the COVID-19 pandemic, ca...
Autores principales: | Caronna, E., José Gallardo, V., Alpuente, A., Torres-Ferrus, M., Sánchez-Mateo, N.M., Viguera-Romero, J., López-Veloso, A.C., López-Bravo, A., Gago-Veiga, A.B., Irimia Sieira, P., Porta-Etessam, J., Santos-Lasaosa, S., Pozo-Rosich, P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Sociedad Española de Neurología. Published by Elsevier España, S.L.U.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7973059/ https://www.ncbi.nlm.nih.gov/pubmed/33832802 http://dx.doi.org/10.1016/j.nrl.2021.03.003 |
Ejemplares similares
-
Safety of anti-CGRP monoclonal antibodies in patients with migraine during the COVID-19 pandemic: Present and future implications
por: Caronna, E., et al.
Publicado: (2021) -
Anti-CGRP monoclonal antibodies in chronic migraine with medication overuse: real-life effectiveness and predictors of response at 6 months
por: Caronna, Edoardo, et al.
Publicado: (2021) -
In search of a gold standard patient-reported outcome measure to use in the evaluation and treatment-decision making in migraine prevention. A real-world evidence study
por: Alpuente, Alicia, et al.
Publicado: (2021) -
Influence of headache pain intensity and frequency on migraine-related disability in chronic migraine patients treated with OnabotulinumtoxinA
por: Torres-Ferrus, Marta, et al.
Publicado: (2020) -
A study of differential microRNA expression profile in migraine: the microMIG exploratory study
por: Gallardo, V. J., et al.
Publicado: (2023)